Bradley Monk
Professor · University of Central Florida/HCA Florida Healthcare
Credentials: · · · · · ·
History
- 1990–1994
Obstetrics and Gynecology
Research
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
New England Journal of Medicine · 2016 · 2,004 citations
Incorporation of bevacizumab in the primary treatment of ovarian cancer
New England Journal of Medicine · 2011 · 1,905 citations
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
New England Journal of Medicine · 2019 · 1,824 citations
- RC
91 papers
85 papers · 9 as a resident
83 papers
- RB
60 papers · 11 as a resident
46 papers
45 papers · 8 as a fellow
44 papers
39 papers · 5 as a resident
Grants
- 2001–2006
Strategies Against HPV Related Genital Diseases in Women
National Cancer Institute · K23
Contact PI · $635.9K · University of California-Irvine
Clinical trials
- 2022–2027
ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer
Principal investigator · Active not recruiting · Phase 2
OncoC4, Inc.
- 2021–2022
A Multi-center Study of VAL-083 in Patients With Recurrent Platinum Resistant Ovarian Cancer
Principal investigator · Withdrawn · Phase 1, Phase 2
DelMar Pharmaceuticals, Inc.
- 2019–2023
Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA)
Principal investigator · Completed · Phase 3
AstraZeneca
- 2011–2016
Principal investigator · Completed · Phase 2
National Cancer Institute (NCI)